Search results for "OUTCOME"

showing 10 items of 5148 documents

Efficacy and safety of allergen immunotherapy in patients with allergy to molds: A systematic review

2018

BACKGROUND Allergen immunotherapy (AIT) with mould extracts has been performed for many years but the final demonstration of its clinical efficacy is still missing, due to the small number of studies and their inconsistent results. OBJECTIVE To systematically review efficacy and safety of AIT for the treatment of respiratory allergies to moulds. DESIGN The primary outcomes were safety and reduction of symptoms (Symptom Score, SS) and medication use (Medication Score, MS) in patients treated with AIT compared to controls. The strength of the evidence was graded based on the risk of bias, consistency and magnitude of effect, according to the GRADE Working Group's guide. DATA SOURCES Medline, …

Allergen immunotherapymedicine.medical_specialtyAllergyAntigens FungalImmunologyMEDLINECochrane LibraryPlacebo03 medical and health sciences0302 clinical medicinePharmacotherapyInternal medicineHypersensitivityHumansImmunology and AllergyMedicineAnti-Asthmatic Agents030212 general & internal medicineAsthmaClinical Trials as Topicbusiness.industryFungiAllergensmedicine.diseasePhenotypeTreatment Outcome030228 respiratory systemDesensitization ImmunologicSample size determinationbusinessClinical & Experimental Allergy
researchProduct

COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overvi…

2021

To date, four vaccines have been authorised for emergency use and under conditional approval by the European Medicines Agency to prevent COVID-19: Comirnaty, COVID-19 Vaccine Janssen, Spikevax (previously COVID-19 Vaccine Moderna) and Vaxzevria (previously COVID-19 Vaccine AstraZeneca). Although the benefit–risk profile of these vaccines was proven to be largely favourable in the general population, evidence in special cohorts initially excluded from the pivotal trials, such as pregnant and breastfeeding women, children/adolescents, immunocompromised people and persons with a history of allergy or previous SARS-CoV-2 infection, is still limited. In this narrative review, we critically overv…

AllergyIMPACTCOVID-19 VaccineBreastfeedingReview ArticleToxicologySettore MED/42 - Igiene Generale E ApplicataCLINICAL CHARACTERISTICSPregnancyPharmacology (medical)Pregnancy Complications InfectiousChildOUTCOMESeducation.field_of_studyCANCERVaccinationEuropeCORONAVIRUS DISEASE 2019 CLINICAL CHARACTERISTICS CANCER RECIPIENTS SEVERITY OUTCOMES IMPACT RATESBreast FeedingChild PreschoolPractice Guidelines as TopicFemale2019-nCoV Vaccine mRNA-1273HumanAdultmedicine.medical_specialtyCOVID-19 Vaccines2019-nCoV Vaccine mRNA-1273; Adolescent; Adult; BNT162 Vaccine; Breast Feeding; COVID-19; COVID-19 Vaccines; ChAdOx1 nCoV-19; Child; Child Preschool; Europe; Female; Humans; Infant; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications Infectious; SARS-CoV-2; Hypersensitivity; Immunocompromised HostAdolescentSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PopulationMEDLINECORONAVIRUS DISEASE 2019Immunocompromised HostChAdOx1 nCoV-19medicineHypersensitivityHumansRATESeducationBNT162 VaccinePharmacologyPregnancybusiness.industrySARS-CoV-2COVID-19Infantmedicine.diseaseVaccine efficacyRECIPIENTSSEVERITYFamily medicinePregnancy Complications Infectioubusiness
researchProduct

An alternative allergen:adjuvant formulation potentiates the immunogenicity and reduces allergenicity of a novel subcutaneous immunotherapy product f…

2012

Background Subcutaneous specific immunotherapy (SCIT) has proven sustained clinical efficacy against allergy. The recommended regimen for SCIT is a gradual updosing over a period of weeks. Commonly, in commercial products for SCIT, the specific allergen is formulated with an adjuvant, most often in the form of aluminium hydroxide (AlOH). It has been shown that allergen-specific IgG antibodies are induced as a result of successful SIT. Objective To investigate the possibility of optimizing the formulation of AlOH-based grass-pollen allergy vaccines for SCIT in a way that allows for shorter updosing regimens while maintaining the immunogenicity of the vaccine. Methods Mice were immunized with…

AllergyInjections SubcutaneousT-LymphocytesT cellmedicine.medical_treatmentImmunologyAluminum HydroxidePharmacologyPoaceaemedicine.disease_causePhleumMiceAllergenAdjuvants ImmunologicAnimalsHumansImmunology and AllergyMedicineMice Inbred BALB CbiologyPlant Extractsbusiness.industryImmunogenicityRhinitis Allergic SeasonalAllergen extractAllergensmedicine.diseasebiology.organism_classificationTreatment Outcomemedicine.anatomical_structureDesensitization ImmunologicImmunoglobulin GPhleumImmunologybiology.proteinPollenFemaleAntibodybusinessAdjuvantClinical & Experimental Allergy
researchProduct

Probiotics Properties: A Focus on Pregnancy Outcomes.

2021

A healthy microbiome plays an important role in the prevention of illness and maintenance of overall health, including reproductive health. Although the therapeutic advantages of probiotics have been shown to run across multiple organ systems, their role in pregnancy is not well explored. The aim of this review is to highlight the potential advantages and adverse effects of probiotics in pregnancy. Data were collected from the literature over the past decade using PubMed, Medline, Google Scholar, Ovid, Scopus, and Science Direct. A total of 40 articles were utilized in this review. Collected data indicated that prenatal and post-natal supplementation with lactobacilli alone or lactobacilli …

AllergyMicrobiotaProbioticsPregnancy OutcomeObstetrics and GynecologyInfantOpportunistic infectionDiabetes GestationalLactobacillusBreast FeedingReproductive MedicineLactobacilliPregnancyReproductive healthHumansFemaleEuropean journal of obstetrics, gynecology, and reproductive biology
researchProduct

Faldaprevir (BI 201335), BI 207127 and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results

2013

Background Faldaprevir (BI 201335) and deleobuvir (BI 207127) are direct-acting antiviral agents under development for the treatment of chronic HCV infection. This article describes the final results of the Phase Ib SOUND-C1 study that evaluated the interferon-free oral combination of faldaprevir, deleobuvir and ribavirin in 32 treatment-naive patients infected with HCV genotype 1. Methods Patients were randomized to receive deleobuvir 400 mg ( n=15) or 600 mg ( n=17) three times daily plus faldaprevir 120 mg once daily and weight-based ribavirin for 4 weeks. Interferon-free therapy was followed by response-guided faldaprevir plus pegylated interferon-α2a/ribavirin to week 24 or 48. Results…

Aminoisobutyric AcidsProline[SDV]Life Sciences [q-bio]610 Medicine & healthHepacivirusAntiviral AgentsDrug Administration SchedulePolyethylene GlycolsTherapy naive03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHcv genotype 1LeucineRibavirinMedicine2736 Pharmacology (medical)Pharmacology (medical)Oral therapy030304 developmental biologyPharmacology0303 health sciencesbusiness.industryRibavirinDeleobuvirInterferon-alpha2725 Infectious DiseasesHepatitis C ChronicViral LoadVirologyRecombinant Proteins3. Good healthThiazolesInfectious DiseasesTreatment Outcome10219 Clinic for Gastroenterology and Hepatology3004 PharmacologychemistryAcrylatesFaldaprevirQuinolines030211 gastroenterology & hepatologyBenzimidazolesDrug Therapy CombinationbusinessOligopeptides
researchProduct

Rational Management of Macroglossia Due to Acquired Systemic Amyloidosis: Does Surgery Play a Role?

2008

Amyloidmedicine.medical_specialtyFatal outcomemedicine.medical_treatmentMEDLINEFatal OutcomeTracheostomyMacroglossiaTonguemedicineMacroglossiaHumansGastrostomyGlossectomybusiness.industryContraindicationsAmyloidosisAmyloidosisMiddle Agedmedicine.diseaseSystemic amyloidosisGastrostomySurgerymedicine.anatomical_structureOtorhinolaryngologyGlossectomyFemaleImmunoglobulin Light ChainsSurgeryOral Surgerymedicine.symptomMultiple MyelomabusinessJournal of Oral and Maxillofacial Surgery
researchProduct

Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real life clinical practice: a nationwide multicenter retrospective observ…

2018

A few studies have reported the safety profile of interleukin (IL)-1 blockers from real life. The aim of this study is to describe anakinra (ANA) and canakinumab (CAN) safety profile in children and adults, based on data from a real-life setting. Demographic, clinical, and therapeutic data from patients treated with ANA and CAN were retrospectively collected and analyzed. Four hundred and seventy five patients were enrolled; ANA and CAN were prescribed in 421 and 105 treatment courses, respectively. During a mean follow-up of 24.39 ± 27.04 months, 89 adverse events (AE) were recorded; 13 (14.61%) were classified as serious AE (sAE). The overall estimated rate of AE and sAE was 8.4 per 100 p…

Anakinra; Autoinflammatory disorders; Canakinumab; Interleukin-1; Safety profile0301 basic medicineMaleSettore MED/16 - REUMATOLOGIAAutoinflammatory disorders0302 clinical medicineRetrospective StudieAnakinra; Autoinflammatory disorders; Canakinumab; Interleukin-1; Safety profile; RheumatologyChildAntibodies MonoclonalGeneral MedicineMiddle AgedAnakinraTreatment OutcomeAutoinflammationFemaleCohort studymedicine.drugHumanAdultmedicine.medical_specialtyAdolescentLogistic ModelCanakinumabNeutropeniaAntibodies Monoclonal HumanizedAutoimmune DiseaseAutoimmune Diseases03 medical and health sciencesYoung AdultRheumatologyInternal medicineInjection site reactionmedicineHumansAnakinra Autoinflammatory disorders Canakinumab Interleukin-1 Safety profile Adolescent Adult Antibodies Monoclonal Antibodies Monoclonal Humanized Autoimmune Diseases Child Female Humans Interleukin 1 Receptor Antagonist Protein Logistic Models Male Middle Aged Retrospective Studies Treatment Outcome Young AdultAdverse effectRetrospective Studies030203 arthritis & rheumatologyAnakinrabusiness.industryRetrospective cohort studymedicine.diseaseCanakinumabInterleukin 1 Receptor Antagonist ProteinLogistic Models030104 developmental biologyAutoinflammatory disorderSafety profileObservational studybusinessInterleukin-1
researchProduct

Fissurectomy and anoplasty in posterior normotensive chronic anal fissure.

2021

Purpose: Anal Fissure (AF) is the second most frequent proctological disease in Italy. Chronic AF (CAF) most common located at the posterior anal commissure (CAPF). CAPF are thought to be associated with hypertonic internal anal sphincter (IAS) but manometric findings showed that a normotonic IAS is present in the 20-40%. Sphincterotomy is often recommended as treatment of choice for CAF independently from IAS tone; nevertheless, this approach appears less logical for CAF with normotonic IAS, as in those cases there’s a higher risk of post-operative anal incontinence. The aim of this study is to evaluate the results of fissurectomy and anoplasty with V-Y cutaneous advancement flap, as treat…

Anal fissure; Anoplasty; Fissurectomy; Proctology; Sphincterectomy; Chronic Disease; Humans; Prospective Studies; Treatment Outcome; Digestive System Surgical Procedures; Fissure in AnoTreatment Outcomeanal fissuresphincterectomyChronic DiseaseHumansfissurectomyOriginal ArticleanoplastyFissure in AnoProspective StudiesproctologyDigestive System Surgical ProceduresActa bio-medica : Atenei Parmensis
researchProduct

TAP Block Prior to Open Ventral Hernia Repair Improves Surgical Outcome.

2022

Abstract Background Ventral hernias commonly affect patients after major abdominal surgery. To reduce postoperative pain, the effects of the transversus abdominis plane (TAP) block, epidural analgesia and medication-only protocol have been investigated. The primary outcome was the cumulative dosage of opioids (morphine milligram equivalents MME), of acetaminophen and diclofenac for postoperative pain control on postoperative day (POD) 0, 1, and 2. Secondary outcomes were length of stay (LOS) and the pain scale rating using the numeric rating scale (NRS) on POD 0, 1, and 2. Methods The data were retrospectively extracted from the charts of the patients admitted for a surgical operation for O…

Analgesia EpiduralAnalgesics OpioidPain PostoperativeDiclofenacTreatment OutcomeHumansSurgeryHernia VentralAbdominal MusclesRetrospective StudiesWorld journal of surgery
researchProduct

Intraoperative cell salvage in ruptured abdominal aortic aneurysms

2010

Aim. The aim of this study was to evaluate the impact of intraoperative cell salvage (ICS) on the early outcome after open repair (OR) of ruptured abdominal aortic aneurysm (rAAA). Methods. This is a retrospective review of 73 consecutive patients who underwent emergency OR of infrarenal rAAA with ICS between 2005 and 2008 (Group I), compared to 51 repairs from 2002-2004 with no ICS (Group II). In addition, a transfusion protocol of platelets and fresh frozen plasma (FFP) administration on admission and during surgery was adopted in patients in Group I to maintain coagulation competence. Results. ICS reduced bank blood demand by 63.6% (from 11 to 4 units, P<0.001) compared to controls, and …

Aneurysm ruptured surgical procedures blood platelets plasma treatment outcomeSettore MED/22 - Chirurgia Vascolare
researchProduct